AstraZeneca PLC (AZN) EPS Diluted: 6.54
Is AstraZeneca PLC’s EPS diluted high or low?
AstraZeneca PLC's EPS diluted of 6.54 is 128% above its 5-year average of 2.87, near the high end of its 5-year range (0.08–6.54).
48.81% above its 12-month average of 4.39.
AZN EPS Diluted Chart
AZN Average EPS Diluted Chart
AZN Current vs Average EPS Diluted Chart
AZN EPS Diluted Metrics
EPS DILUTED
6.54
EPS DILUTED AVG TTM
4.39
EPS DILUTED AVG 3Y
3.68
EPS DILUTED AVG 5Y
2.87
EPS DILUTED AVG 10Y
2.48
EPS DILUTED AVG 15Y
3.01
EPS DILUTED AVG 20Y
3.24
CURRENT VS TTM AVG
+48.81%
CURRENT VS 3Y AVG
+77.84%
CURRENT VS 5Y AVG
+127.74%
CURRENT VS 10Y AVG
+163.32%
CURRENT VS 15Y AVG
+117.37%
CURRENT VS 20Y AVG
+101.91%
AstraZeneca PLC EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC EPS Diluted FAQ
- What is the EPS diluted for AstraZeneca PLC (AZN)?
- The EPS diluted for AZN stock is 6.54.
- Is AstraZeneca PLC's EPS diluted high or low?
- AstraZeneca PLC's EPS diluted of 6.54 is 128% above its 5-year average of 2.87, near the high end of its 5-year range (0.08–6.54).
- What is the TTM average EPS diluted for AstraZeneca PLC (AZN)?
- The TTM average EPS diluted for AZN stock is 4.39.
- What is the 3Y average EPS diluted for AstraZeneca PLC (AZN)?
- The 3Y average EPS diluted for AZN stock is 3.68.
- What is the 5Y average EPS diluted for AstraZeneca PLC (AZN)?
- The 5Y average EPS diluted for AZN stock is 2.87.
- What is the 10Y average EPS diluted for AstraZeneca PLC (AZN)?
- The 10Y average EPS diluted for AZN stock is 2.48.
- What is the 15Y average EPS diluted for AstraZeneca PLC (AZN)?
- The 15Y average EPS diluted for AZN stock is 3.01.
- What is the 20Y average EPS diluted for AstraZeneca PLC (AZN)?
- The 20Y average EPS diluted for AZN stock is 3.24.
AstraZeneca PLC EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 6.54 |
| 2024-12-31 | 2.25 |
| 2023-12-31 | 3.81 |
| 2022-12-31 | 2.11 |
| 2021-12-31 | 0.08 |
| 2020-12-31 | 2.44 |
| 2019-12-31 | 1.03 |
| 2018-12-31 | 1.70 |
| 2017-12-31 | 2.37 |
| 2016-12-31 | 2.76 |
| 2015-12-31 | 2.23 |
| 2014-12-31 | 0.98 |
| 2013-12-31 | 2.04 |
| 2012-12-31 | 4.93 |
| 2011-12-31 | 7.30 |
| 2010-12-31 | 5.57 |
| 2009-12-31 | 5.19 |
| 2008-12-31 | 4.20 |
| 2007-12-31 | 3.73 |
| 2006-12-31 | 3.85 |
| 2005-12-31 | 2.91 |
| 2004-12-31 | 218.00 |
| 2003-12-31 | 178.00 |
| 2002-12-31 | 1.64 |
| 2001-12-31 | 1.65 |
| 2000-12-31 | 1.43 |
| 1999-12-31 | 0.64 |
| 1998-12-31 | 1.46 |
| 1997-12-31 | 1.27 |
| 1996-12-31 | 1.16 |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot